PALISADE BIO, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
PALISADE BIO, INC. (PALI) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $1.12 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-20.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-03-20
- PALISADE BIO, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.36, a 95.15% decline year-over-year.
- PALISADE BIO, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2022-03-31 was $48.67.
- PALISADE BIO, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2016-03-31 was $0.00, a 100.00% decline year-over-year.
- PALISADE BIO, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2015-03-31 was $2.40, a 66.67% increase year-over-year.
- PALISADE BIO, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $1.12, a 75.33% decline from fiscal 2024.
- PALISADE BIO, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $4.54, a 78.23% decline from fiscal 2023.
- PALISADE BIO, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $20.85, a 48.29% decline from fiscal 2022.
- PALISADE BIO, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $40.32, a 65.24% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $1.12 10-K · filed 2026-03-20 | |||||||
| 2024-12-31 | $4.54 10-K · filed 2026-03-20 | |||||||
| 2023-12-31 | $20.85 10-K · filed 2025-03-24 | $1.39 10-K · filed 2024-03-26 | ||||||
| 2023-09-30 | $1.64 10-Q · filed 2023-11-09 | |||||||
| 2023-06-30 | $1.80 10-Q · filed 2023-08-10 | |||||||
| 2023-03-31 | $2.36 10-Q · filed 2023-05-11 | |||||||
| 2022-12-31 | $40.32 10-K · filed 2024-03-26 | |||||||
| 2022-09-30 | $40.32 10-Q · filed 2023-11-09 | $0.81 10-Q · filed 2022-11-14 | ||||||
| 2022-06-30 | $44.48 10-Q · filed 2023-08-10 | $0.89 10-Q · filed 2022-08-15 | ||||||
| 2022-03-31 | $48.67 10-Q · filed 2023-05-11 | $0.97 10-Q · filed 2022-05-13 | ||||||
| 2021-12-31 | $116.00 10-K · filed 2023-03-22 | $3.08 10-K · filed 2022-03-17 | ||||||
| 2021-09-30 | $17.72 10-Q · filed 2022-11-14 | |||||||
| 2021-06-30 | $17.72 10-Q · filed 2022-08-15 | $0.00 10-Q · filed 2021-08-23 | ||||||
| 2020-12-31 | $26.85 10-K · filed 2022-03-17 | |||||||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-09 | |||||||
| 2015-12-31 | $0.54 10-K · filed 2016-03-14 | |||||||
| 2015-09-30 | $0.54 10-Q · filed 2015-11-09 | |||||||
| 2015-06-30 | $1.64 10-Q · filed 2015-08-10 | |||||||
| 2015-03-31 | $2.40 10-Q · filed 2015-05-08 | |||||||
| 2014-12-31 | $0.89 10-K · filed 2015-03-16 | |||||||
| 2014-09-30 | $0.89 10-Q · filed 2014-11-07 | |||||||
| 2014-06-30 | $1.53 10-Q · filed 2014-08-08 | |||||||
| 2014-03-31 | $1.44 10-Q · filed 2014-05-12 | |||||||
| 2013-12-31 | $0.00 10-K · filed 2014-03-10 | |||||||
| 2013-09-30 | $0.00 10-Q · filed 2013-11-12 | |||||||
| 2013-06-30 | $0.00 10-Q · filed 2013-08-08 | |||||||
| 2013-03-31 | $0.00 10-Q · filed 2013-05-10 | |||||||
| 2012-12-31 | $0.00 10-K · filed 2013-03-15 | |||||||
| 2012-09-30 | $0.00 10-Q · filed 2012-11-09 | |||||||
| 2012-06-30 | $0.00 10-Q · filed 2012-08-09 | |||||||
| 2011-12-31 | $0.00 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |